These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

735 related articles for article (PubMed ID: 19250932)

  • 1. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.
    Sohn KA; Cruciani-Guglielmacci C; Kassis N; Clément L; Ouali F; Caüzac M; Lebègue N; Berthelot P; Caignard DH; Pégorier JP; Renard P; Dacquet C; Ktorza A; Magnan C;
    Eur J Pharmacol; 2009 Apr; 608(1-3):104-11. PubMed ID: 19250932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
    Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
    Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs.
    Uchino H; Kim T; Lam TK; Yoshii H; Klement P; Williams W; Kawamori R; Giacca A
    Metabolism; 2005 Sep; 54(9):1250-8. PubMed ID: 16125538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
    Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
    Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of free fatty acid-induced insulin resistance on plasma ghrelin level: an experimental study with rats].
    Li L; Yang GY
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1645-8. PubMed ID: 15569462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adiponectin concentrations increase during acute FFA elevation in humans treated with rosiglitazone.
    Krzyzanowska K; Mittermayer F; Krugluger W; Roden M; Schernthaner G; Wolzt M
    Horm Metab Res; 2007 Oct; 39(10):769-72. PubMed ID: 17952842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
    Wang ZJ; Liu Q; Li PP; Zou CH; Shen ZF
    Eur J Pharmacol; 2008 Feb; 580(1-2):277-83. PubMed ID: 18048028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sodium salicylate on oxidative stress and insulin resistance induced by free fatty acids.
    He B; Zhao S; Zhang W; Li Y; Han P
    Hepatobiliary Pancreat Dis Int; 2010 Feb; 9(1):49-53. PubMed ID: 20133229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-fat- and lipid-induced insulin resistance in rats: the comparison of glucose metabolism, plasma resistin and adiponectin levels.
    Li L; Yang G; Li Q; Tang Y; Li K
    Ann Nutr Metab; 2006; 50(6):499-505. PubMed ID: 17191023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo.
    Park E; Wong V; Guan X; Oprescu AI; Giacca A
    J Endocrinol; 2007 Nov; 195(2):323-31. PubMed ID: 17951543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta.
    Lam TK; Yoshii H; Haber CA; Bogdanovic E; Lam L; Fantus IG; Giacca A
    Am J Physiol Endocrinol Metab; 2002 Oct; 283(4):E682-91. PubMed ID: 12217885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
    Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
    Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions.
    Chen Y; Li Y; Wang Y; Wen Y; Sun C
    Metabolism; 2009 Dec; 58(12):1694-702. PubMed ID: 19767038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
    Lessard SJ; Rivas DA; Chen ZP; Bonen A; Febbraio MA; Reeder DW; Kemp BE; Yaspelkis BB; Hawley JA
    Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
    Chakrabarti R; Misra P; Vikramadithyan RK; Premkumar M; Hiriyan J; Datla SR; Damarla RK; Suresh J; Rajagopalan R
    Eur J Pharmacol; 2004 May; 491(2-3):195-206. PubMed ID: 15140637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
    Berthiaume M; Laplante M; Tchernof A; Deshaies Y
    Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARgamma agonist induced cardiac enlargement is associated with reduced fatty acid and increased glucose utilization in myocardium of Wistar rats.
    Edgley AJ; Thalén PG; Dahllöf B; Lanne B; Ljung B; Oakes ND
    Eur J Pharmacol; 2006 May; 538(1-3):195-206. PubMed ID: 16674938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites.
    Lam TK; van de Werve G; Giacca A
    Am J Physiol Endocrinol Metab; 2003 Feb; 284(2):E281-90. PubMed ID: 12531742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
    Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
    Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.
    Ye JM; Iglesias MA; Watson DG; Ellis B; Wood L; Jensen PB; Sørensen RV; Larsen PJ; Cooney GJ; Wassermann K; Kraegen EW
    Am J Physiol Endocrinol Metab; 2003 Mar; 284(3):E531-40. PubMed ID: 12556350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.